welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
study id #: NCT01484678
condition: Duchenne Muscular Dystrophy
status: active, not recruiting
purpose:The purpose of this research study is to determine the potential of magnetic resonance imaging to monitor disease progression and to serve as an objective outcome measure for clinical trials in Duchenne Muscular Dystrophy (DMD). The investigators also hope to learn more about the changes that occur in muscles of the lower leg and arm in boys with DMD.
The investigators will compare the muscles of ambulatory or non-ambulatory boys with DMD with muscles of healthy children of the same age and monitor disease progression in boys with DMD over a 5-10 year period. The amount of muscle damage and fat that the investigators measure will also be related to performance in daily activities, such as walking and the loss of muscle strength. In a small group of subjects the investigators will also assess the effect of corticosteroid drugs on the muscle measurements.
mechanism of action: No pharmaceutical intervention
results: https://clinicaltrials.gov/ct2/show/results/NCT01484678
last updated: May 28, 2020
rareRelated
-
Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)The aim of this study is to provide cont...
-
Study of ACE-031 in Subjects With Duchenne Muscular DystrophyThe purpose of this study is to determin...
-
There’s No Straight Line in Drug DevelopmentToday’s FDA disapproval of Sarepta’s...
-
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship ProgramCAMBRIDGE, Mass., Sept. 05, 2019 (GLOB...
-
A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)The purpose of this study is to evaluate...
-
The Effect of Kinesiology Taping on Balance in Duchenne Muscular DystrophyInvestigators investigated that the effe...
-
Shape Therapeutics’s RNA Editing Gene Therapy Platform Focused on Curing Genetic DiseasesShape Therapeutics, Inc. (ShapeTx), a de...
-
FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary...FibroGen, Inc., a biopharmaceutical comp...
-
Duchenne UK: DMD Patient and Caregiver Survey Resultshttps://www.youtube.com/watch?v=d2EpSB8R...